For example, two meta-analyses recently concluded that breast cancer patients with amplification of the topoisomerase 2A (TOP2A) gene have more clinical benefit from treatment with topoisomerase II inhibitors than patients with normal TOP2A gene number in their cancer cells (17–19). The gene discussed is TOP2A; the disease is breast carcinoma.